×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENLV – enlivex therapeutics ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENLV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
08:00 am
enlv
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Low
Report
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
10/30
08:00 am
enlv
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
Medium
Report
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
9/27
08:07 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
9/26
08:30 am
enlv
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Medium
Report
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
9/24
08:30 am
enlv
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Low
Report
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
9/11
01:46 pm
enlv
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy Wed, Sep 11, 2024, 6:00 PM GMT+2 3 min read 0 In this article: Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Re
Low
Report
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy Wed, Sep 11, 2024, 6:00 PM GMT+2 3 min read 0 In this article: Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Re
9/9
08:08 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
8/28
07:57 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:26 am
enlv
Form 6-K Enlivex Therapeutics For: Nov 12
Low
Report
Form 6-K Enlivex Therapeutics For: Nov 12
11/8
04:35 pm
enlv
Form 6-K Enlivex Therapeutics For: Nov 08
Low
Report
Form 6-K Enlivex Therapeutics For: Nov 08
10/31
04:06 pm
enlv
Form 6-K Enlivex Therapeutics For: Oct 31
Low
Report
Form 6-K Enlivex Therapeutics For: Oct 31
10/30
08:01 am
enlv
Form 6-K Enlivex Therapeutics For: Oct 30
Medium
Report
Form 6-K Enlivex Therapeutics For: Oct 30
10/15
06:12 am
enlv
Form 6-K/A Enlivex Therapeutics For: Oct 14
Medium
Report
Form 6-K/A Enlivex Therapeutics For: Oct 14
9/26
08:32 am
enlv
Form 6-K Enlivex Therapeutics For: Sep 26
Medium
Report
Form 6-K Enlivex Therapeutics For: Sep 26
9/24
08:33 am
enlv
Form 6-K Enlivex Therapeutics For: Sep 24
Low
Report
Form 6-K Enlivex Therapeutics For: Sep 24
9/11
08:30 am
enlv
Form 6-K Enlivex Therapeutics For: Sep 11
Low
Report
Form 6-K Enlivex Therapeutics For: Sep 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/16
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
13.1%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
TOP News Decliners
3/18
Form 6-K Enlivex Therapeutics For: Mar 18
-29.3%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: